Date: 2017-04-17

Type of information: Nomination


Company: Juno Therapeutics (USA - WA)

Therapeutic area:

Type agreement: nomination

Action mechanism:



  • • On April 17, 2017, Juno Therapeutics announced it has appointed Sunil Agarwal, M.D., as president of research and development. With Dr. Agarwal’s appointment, Juno will bring research and development under one leader responsible for the execution of Juno’s drug development pipeline, integration of translational insights into ongoing programs, and the prioritization of research and development initiatives. Prior to joining Juno, Dr. Agarwal was Chief Medical Officer, Executive Vice President at Ultragenyx. Prior to his tenure at Ultragenyx, he worked in several senior leadership roles at Genentech, most recently as Senior Vice President, Global Development Head, Ophthalmology, Metabolism, Neuroscience, Immunology and Infectious Diseases. He was responsible for the global development of programs in these areas from proof of concept (PoC) through Phase IV. He was also a member of both the Genentech Research and Early Development (gRED) and Pharma Research and Early Development (pRED) committees. At Juno, Dr. Agarwal will report to Mr. Bishop and will be a member of the firm’s Executive Committee.

Financial terms:

Latest news:

Is general: Yes